Literature DB >> 6825129

Phase II trial of spirogermanium for treatment of advanced breast cancer.

G Falkson, H C Falkson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6825129

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  6 in total

Review 1.  Nephrotoxicity and neurotoxicity in humans from organogermanium compounds and germanium dioxide.

Authors:  A G Schauss
Journal:  Biol Trace Elem Res       Date:  1991-06       Impact factor: 3.738

Review 2.  An assessment of current achievements in the systemic management of breast cancer.

Authors:  M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

3.  Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.

Authors:  M Slavik; O Blanc; J Davis
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro.

Authors:  B T Hill; A S Bellamy; S Metcalfe; P J Hepburn; J R Masters; R D Whelan
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 5.  Complexes of metals other than platinum as antitumour agents.

Authors:  P Köpf-Maier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Effects of germanium and silicon on bone mineralization.

Authors:  C D Seaborn; F H Nielsen
Journal:  Biol Trace Elem Res       Date:  1994-08       Impact factor: 3.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.